Robotics – Page 11 – Selby Spine

September 07, 2016

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the launch of a new brand identity for the ALF-X Robotic Surgical System, which henceforth will be known as The Senhance™ Surgical Robotic System (“Senhance”).

“We are pleased to announce the new brand identity for our multiport surgical robotic system,” said Todd M. Pope, President and CEO of TransEnterix. “This is a pivotal point in our growth strategy and we believe Senhance speaks directly to the benefits experienced with our system.”

Mr. Pope continued: “Our goal is to advance minimally invasive surgery and the tools surgeons have at their disposal to provide patients with the best possible care while also providing a more attractive value proposition to the hospital. Senhance is designed to enhance laparoscopic surgery and specifically empowers the senses of the surgeon in ways that were never previously possible. The security of haptics and the convenience of eye sensing camera control are meaningful ways that technology can provide a further extension of the surgeon’s skill.”

The new logo, evocative of a thumb-print combined with circuitry, is a representation of the strong connection that Senhance provides between the surgeon and technology.

Senhance carries the CE Mark for use in general surgery, gynecology, urology and thoracic surgery. TransEnterix is actively preparing a submission for U.S. FDA Clearance for Senhance.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to The Senhance™ Surgical Robotic System and the SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether Senhance speaks directly to the benefits both surgeons and patients experience with our Senhance system; whether Senhance is designed to enhance laparoscopic surgery and specifically empower the senses of the surgeon in ways never before provided. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For US) Hannah Dunning, +1 415-618-8750
TransEnterix-SVC@sardverb.com

September 1, 2016 – By Carolyn LaWell

Disc Replacement

Zimmer Biomet’s $1 billion acquisition of LDR and its Mobi-C cervical disc assets and Medtronic’s FDA Premarket Approval for the Prestige LP 2-level application changed the game in the U.S. 2-level cervical disc replacement arena.

Mobi-C had been the only 2-level disc approved on the U.S. market. Prior to Zimmer Biomet’s purchase of the technology, LDR was able to expand reimbursement coverage, update label claims and publish peer-reviewed papers that resulted in Mobi-C’s sales growth, which increased 80% in 2015 vs. 2014.

Further, in April 2016, LDR reported that Mobi-C had surpassed $100 million in cumulative U.S. revenue since its 2013 launch. Half of the Mobi-C units sold address 1-level indications and half are for 2-level indications.

The acquisition of LDR allows Zimmer Biomet to increase its share of the worldwide spine market from 4% to 5%, according to ORTHOWORLD estimates. While the purchase also expands Zimmer Biomet’s traditional cervical and lumbar offerings, Mobi-C is presumably the technology that attracted Zimmer Biomet to LDR, primarily.

Medtronic’s entry into the 2-level market is expected to put competitive pressure on Zimmer Biomet’s purchase. The 2-level discs will be sold in a small market that faces a lack of reimbursement, compared to 1-level discs and fusion. To dive into specifics, >50 million lives are covered for Mobi-C’s 2-level procedure. The total artificial disc market is expected to reach ~$275 million in 2016, according to estimates in the ORTHOWORLD report, Cervical and Lumbar Artificial Disc Profiles.

READ THE REST HERE

TORONTO, ON–(Marketwired – August 29, 2016) – Titan Medical Inc. (TSX: TMD) (OTCQX: TITXF), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that Dr. Dennis Fowler will resign from Titan effective August 31, 2016. Dr. Fowler has been with Titan since March 2014, most recently as Executive Vice President of Clinical and Regulatory Affairs. James Shore, Director of Quality, and Christopher Seibert, Vice President of Corporate Accounts, will be assuming Dr. Fowler’s responsibilities on an interim basis while a search is initiated. Mr. Shore, in addition to his responsibilities in quality will assume responsibility for regulatory matters. Mr. Seibert, in addition to his responsibility for corporate accounts, will take on the role of Project Manager for the development of Titan’s robotic surgical system. Both James and Christopher possess industry related experience relevant to their new areas of responsibility. Dr. Fowler is willing to be available to Titan as a consultant.

“I have enjoyed leading the development of the SPORT Surgical System and believe that it has significant potential for both clinical and economic success,” said Dr. Fowler.

“On behalf of the Board of Directors and entire Titan team, I’d like to thank Dr. Fowler for his contributions to the development of the SPORT’ Surgical System and wish him the best in his future endeavors,” said John Hargrove, Chief Executive Officer.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in MIS. The Company’s SPORT’ Surgical System, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view of inside a patient’s body. The SPORT’ Surgical System is designed to enable surgeons to perform a broad set of surgical procedures for general abdominal, gynecologic, and urologic indications. For more information, visit the Company’s website at www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 30, 2016 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Titan Medical Inc.

John Hargrove
Chief Executive Officer
(416) 548-7522 (ext. 151)
john.hargrove@titanmedicalinc.com
www.titanmedicalinc.com

EVC Group, Inc.

Amanda Prior
Aprior@evcgroup.com
(646) 445-4800

Michael Polyviou
mpolyviou@evcgroup.com
(646) 445-4800

MONTPELLIER, France, Aug. 29, 2016 (GLOBE NEWSWIRE) — MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, will be showcasing its ROSA^® robot at three major congresses in September.

The European Association of Neurosurgical Societies (EANS) congress
This event, which takes place in Athens, Greece, from September 4 to 8, gathers around 2,500 experts in surgery of the central nervous system (brain and spine).

At the congress, Dr. Thomas Freiman, a neurosurgeon at Frankfurt University Hospital, will be presenting the results of his study on robotic accuracy in stereotactic procedures with the assistance of ROSA^® Brain (September 7, 11:00 a.m. and 4.30 p.m. local time at Medtech’s Booth #15).

Click here for further information about the congress: http://eans2016.com/

The Congress of Neurological Surgeons (CNS) annual meeting
This congress, scheduled in San Diego, CA, USA, from September 26 to 28, is a major event in the field of neurosurgery, gathering around 3,000 specialists in cranial and spine surgery. Two ROSA^® robots will be showcased at Medtech’s Booth #939 for demonstrations of minimally invasive surgical procedures of the central nervous system.

Click here for further information about the congress: https://www.cns.org/annual-meeting-2016

The annual congress of the European Society for Stereotactic and Functional Neurosurgery (ESSFN)
This scientific meeting, organized from September 28 to October 1 in Madrid, Spain, will gather leading European centers for neurosurgery. Experts in the field will be able to learn about the benefits of using the ROSA^® robot for minimally invasive brain and spine surgery at Medtech’s Booth #15.

On Thursday, September 29, three neurosurgeons of international renown will present their scientific conclusions on robotic activity for minimally invasive brain and spine surgery with the assistance of the ROSA^® robotic surgery system:

Pr. Stephan Chabardes from Grenoble university Hospital in France will be sharing his experience with the ROSA^®robot for deep brain stimulation;
Pr. Mohammad Maarouf, a neurosurgeon at Krankenhaus Merheim in Cologne, Germany, will also discuss his robotic experience with ROSA^® for deep brain stimulation.
Dr. Michel Lefranc, a neurosurgeon at Amiens University Hospital in France, will complete the scientific session with the results of his clinical activity in robotic surgery for the brain and spine.

Click here for further information about the congress: http://www.essfncongress.org/en/

About MEDTECH

Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA^®, an innovative technological device devoted to brain surgery procedures. ROSA^® has been approved in Europe, the United States and Canada.

In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA^® Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.

In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.

In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.

In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA^® Spine, a robotic-assistive device for minimally invasive surgery of the spine.

ORLANDO, Fla., Aug. 30, 2016 — Mazor Robotics Ltd. (TASE:MZOR) (NASDAQGM:MZOR), a developer of innovative guidance systems and complementary products, installed a Renaissance^® Guidance System at Grand Strand Medical Center in Myrtle Beach, SC on July 6, 2016 and has since completed an initial case series. Grand Strand is the second in the state of South Carolina and the ninth HCA-affiliated facility to purchase a Renaissance system. See how Renaissance works.

“One of our main goals is to help improve outcomes for our patients,” said Mark Sims, Chief Executive Officer for Grand Strand Medical Center. “Adding the Renaissance technology to our spine surgery program will elevate the level of quality care available to our community.”

Grand Strand Medical Center is a 301-bed acute care hospital serving residents of Horry and surrounding counties. The hospital offers the only cardiac surgery program, neurosurgery program and pediatric intensive care unit (PICU) in Horry and Georgetown counties and is a designated Level II Trauma Center by DHEC and the American College of Surgeons.

“Now, thanks to Grand Strand Medical Center, spine surgeons and their patients in the Myrtle Beach area have access to our technology” said Mazor Robotics Inc. CEO Christopher Prentice. “We believe in healing through innovation and we look forward to Grand Strand Medical Center redefining the standard of quality care.”

About Mazor
Mazor Robotics (TASE:MZOR) (NASDAQGM:MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in a precise manner. For more information, please visit www.MazorRobotics.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the benefits of the Renaissance technology, and other statements containing the words believes, anticipates, plans, expects, will and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on May 2, 2016 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

CONTACT:Stephani Shipman

Marketing Communications Manager

Mazor Robotics

s.shipman@mazorrobotics-us.com

(407) 591-3461

By AMANDA CICCATELLI – August 23, 2016

Patents are essential to encouraging innovation, but can also limit competition. Intuitive Surgical has dominated the global robotic surgery market (which is expected to hit $11.4 billion by 2020) since the FDA approved its Da Vinci surgical system 16 years ago; today, the machine is used in more than 200,000 operations annually. But many of Intuitive Surgical’s patents begin to expire this year, clearing the way for new technologies to enter the marketplace.

Newcomers include TransEnterix, which is working to commercialize the ALF-X robot, designed to perform minimally invasive surgeries and expected to enter the market in 2017. Google’s Verily, meanwhile, has partnered with Johnson & Johnson to form Verb Surgical, a robotic surgery and medical device that aims to go beyond robotics to what CEO Scott Huennekens calls “digital surgery” — incorporating advanced visualization, instrumentation and analytics.

Josue Villalta of Knobbe Martens recently sat down with Inside Counsel to explore how the patent system has impacted development and innovation in the robotic surgery space and how the expiration of Intuitive Surgical’s patents is expected to impact the marketplace.

The patent system has allowed innovators in the robotic surgery space the ability to protect their innovations while excluding others from practicing the innovations covered by their patents, and in turn, providing barriers to entry into the market for potential competitors. “This is particularly important given that robotic surgical systems are very complex systems that take years to develop, in addition to having to go through an FDA approval process before they can be used in the U.S.,” he explained.

The main player in the robotic surgery space has been Intuitive Surgical, which a search of the public USPTO assignment database indicates has 649 U.S. patents. According to Villalta, however, this number does not capture patents that Intuitive Surgical may have rights to, so the number of patents Intuitive Surgical may have that cover its technology may be much higher.

READ THE REST HERE

Written by Megan Wood – August 25, 2016

Robotic technology is gaining traction in the spine surgery field, allowing surgeons to pre-plan and customize procedures to fit an individual’s anatomy.

In a Mazor Robotics-sponsored webinar, Dennis P. Devito, MD, Children’s Healthcare of Atlanta spine program director, and Kornelis Poelstra, MD, PhD, of Miramar, Fla.-based Sacred Heart Hospital on the Emerald Coast, discussed their experiences using Mazor Robotics technology during spine surgeries.

“Robotics are here to stay and are really going to help us,” said Dr. Poelstra, who has already performed 92 Mazor X cases to date.

Although Dr. Devito relied on freehand technique for the majority of his career, Dr. Devito began using robotic technology in 2006, to “add a dimension of safety and precision” to pedicle screw implantation during spinal surgery.

The United States has 70 hospitals actively using Mazor Robotics technology with 113 centers globally, and 16,000 cases have been performed worldwide.

Dr. Devito’s clinical evidence
Dr. Devito and his colleagues at Children’s Healthcare of Atlanta (CHOA) prospectively collected data on cases using robotic-guided technology.

READ THE REST HERE

August 18, 2016 – by Carlos Correa

SAN DIEGO – A robot created to help surgeons during complicated procedures is bringing new hope to young patients who suffer neurological disorders.

Rady Children’s Hospital is among the few in the country using the technology.

The Rosa Robot has two main parts – a computer brain and a robotic arm. It allows surgeons to create a 3D map of a patient’s brain.

“I think for the future of epilepsy centers and any center that wants to treat epilepsy in the future, this is a vital importance. Rady Children’s is one of the first five hospitals in the country to get this robotic technology to enable us to do that and its important in leading the field for it and continue to treating epilepsy in the best way possible,” said Dr. David Gonda, director of surgical epilepsy, Rady Children’s Hospital.

Rosa is a robotized surgical assistant – the most advanced of its kind.

It’s one of a few being used across the country and six months ago it arrived here at Rady Children’s hospital.

So, far its helped about twenty patients.

Through the robot, doctors are able to look at a 3D image from any angle and at any depth.

READ THE REST HERE

TORONTO, ON–(Marketwired – August 24, 2016) – Titan Medical Inc. (TMD.TO) (TITXF) today announced that it extended the rights granted to Longtai Medical Inc. to negotiate an exclusive marketing, sales and distribution agreement for Titan’s SPORT™ Surgical System in the Asia Pacific Region. The parties have agreed to modify their previous three-month extension to monthly progress reviews. The granting of exclusive rights to negotiate a distribution agreement continues to be part of the Letter Agreement with Longtai Medical Inc.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”). The Company’s SPORT™ Surgical System, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view of inside a patient’s body. The SPORT™ Surgical System is designed to enable surgeons to perform a broad set of surgical procedures for general abdominal, gynecologic, and urologic indications. For more information, visit the Company’s website at www.titanmedicalinc.com.

About Longtai Medical Inc. and Ningbo Long Hengtai International Trade Co. Ltd.

Longtai is a British Columbia corporation associated with Ningbo Long Hengtai International Trade Co. Ltd., a corporation engaged in the distribution of medical devices and related products in China. Longtai is owned by one or more individuals and Shiguang Ling, Chairman of Ningbo Long Hengtai International Trade Co. Ltd.

Ningbo Long Hengtai International Trade Co. Ltd. is engaged in the distribution of medical equipment in China through a substantial network of sub dealers and serves a number of medical device companies including a leading European provider of diagnostic imaging and healthcare IT solutions for hospitals and care centers around the world.

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 30, 2016 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Newer Posts

Search

3 days / 6 sessions
Current Issues in Spine

TransEnterix, Inc. Unveils New Brand Identity for Robotic Surgical System

Contacts

Medtronic, Zimmer Biomet Enter 2-level Cervical Disc and Robotic Markets

Disc Replacement

Titan Medical announces EVP clinical & regulatory affairs Dr. Dennis Fowler to resign

MEDTECH to Showcase Its ROSA Robot at Three Major International Congresses

South Carolina HCA Affiliate, Grand Strand Medical Center, is First in the Region with a Mazor Robotics Renaissance(R) Spine Program

Dominant robotic surgery patents expiring this year. So what’s coming next?

Robotics is here to stay — Drs. Kornelis Poelstra & Dennis Devito on working with Mazor technology

Rosa Robot provides surgical assistance at Rady Children’s Hospital

Titan Medical Extends Negotiating Period With Longtai Medical Inc.

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS